LRMR
Larimar Therapeutics, Inc. NASDAQ Listed Jun 19, 2014$3.68
+0.55%
vs $3.66
Mkt Cap $268.4M
52w Low $2.42
35.7% of range
52w High $5.95
50d MA $3.89
200d MA $3.98
P/E (TTM)
-1.8x
EV/EBITDA
—
P/B
3.4x
Debt/Equity
0.1x
ROE
-212.2%
P/FCF
-2.4x
RSI (14)
61.00
ATR (14)
$0.24
Beta
1.02
50d MA
$3.89
200d MA
$3.98
Avg Volume
1.9M
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Three Bala Plaza East · Bala Cynwyd, PA 19004 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | BMO | -0.53 | -0.31 | +41.5% | 4.10 | +1.0% | -5.1% | -8.0% | -9.5% | +2.8% | +6.0% | — |
| May 13, 2026 | BMO | — | — | — | 4.13 | -1.0% | -0.7% | -5.1% | -8.0% | -9.5% | +2.8% | — |
| May 11, 2026 | BMO | — | — | — | 3.97 | +0.8% | +3.0% | +1.0% | -0.7% | -5.1% | -8.0% | — |
| May 8, 2026 | BMO | — | — | — | 4.00 | +0.5% | -0.8% | +3.0% | +1.0% | -0.7% | -5.1% | — |
| May 7, 2026 | BMO | — | — | — | 4.15 | -0.7% | -3.6% | -0.8% | +3.0% | +1.0% | -0.7% | — |
| May 4, 2026 | BMO | — | — | — | 3.94 | -0.3% | +7.1% | -5.0% | +3.5% | -3.6% | -0.8% | — |
| Mar 19, 2026 | BMO | -0.44 | -0.73 | -65.9% | 4.30 | -0.7% | +4.0% | +0.4% | +4.2% | -2.4% | +2.4% | — |
| Nov 5, 2025 | BMO | -0.39 | -0.61 | -56.4% | 3.80 | -4.2% | -15.3% | +7.8% | -0.3% | +2.6% | +2.3% | — |
| Aug 14, 2025 | BMO | -0.47 | -0.41 | +12.8% | 3.72 | -0.3% | +14.5% | -5.9% | -2.7% | -6.4% | +3.3% | — |
| Apr 30, 2025 | BMO | -0.42 | -0.46 | -9.5% | 2.39 | +0.4% | +10.9% | +7.9% | +3.8% | -9.4% | -21.9% | — |
| Mar 24, 2025 | BMO | -0.29 | -0.45 | -55.2% | 2.54 | +2.4% | -10.2% | +1.3% | -2.6% | +6.7% | -2.1% | — |
| Oct 30, 2024 | BMO | -0.37 | -0.24 | +35.1% | 7.78 | +5.3% | +8.7% | -2.7% | -6.0% | -2.2% | -2.8% | — |
| Aug 7, 2024 | BMO | -0.32 | -0.34 | -6.2% | 7.65 | +1.0% | -6.5% | +4.1% | +3.2% | -0.8% | -0.7% | — |
| May 9, 2024 | BMO | -0.24 | -0.27 | -12.5% | 7.92 | -1.3% | -0.8% | -9.4% | +2.8% | +7.7% | -0.1% | — |
| Mar 14, 2024 | BMO | -0.25 | -0.30 | -20.0% | 9.30 | -2.6% | -6.5% | +0.0% | -4.0% | +2.9% | -0.7% | — |
| Nov 14, 2023 | BMO | -0.23 | -0.21 | +8.7% | 2.39 | +0.4% | +7.1% | +14.5% | +5.5% | +6.5% | -4.6% | — |
| Aug 10, 2023 | BMO | -0.21 | -0.19 | +9.5% | 4.00 | +2.2% | -4.8% | +2.4% | +8.5% | -1.2% | -4.1% | — |
| May 15, 2023 | BMO | -0.25 | -0.15 | +40.0% | 5.06 | -20.4% | -29.1% | +1.7% | +1.1% | +2.2% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27 | JP Morgan | Initiates | Overweight | $9 | $3.47 | $3.61 | +4.0% | +1.4% | -0.9% | -0.3% | +0.9% | -6.0% |
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $4.47 | $4.52 | +1.1% | +0.4% | +4.2% | -2.4% | +2.4% | +3.6% |
| Mar 3 | Wedbush | Maintains | Outperform → Outperform | — | $5.23 | $5.58 | +6.7% | +5.4% | -1.1% | -4.2% | +0.0% | +9.0% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $3.69 | $3.66 | -0.8% | +61.2% | -7.2% | -3.8% | -1.5% | +5.4% |
| Feb 25 | Citigroup | Maintains | Buy → Buy | — | $3.69 | $3.66 | -0.8% | +61.2% | -7.2% | -3.8% | -1.5% | +5.4% |
| Oct 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.15 | $4.22 | +1.7% | +3.1% | +13.8% | -1.2% | -1.9% | +2.1% |
| Sep 30 | Baird | Maintains | Outperform → Outperform | — | $3.38 | $3.33 | -1.5% | -4.4% | +28.5% | +3.1% | +13.8% | -1.2% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $3.38 | $3.33 | -1.5% | -4.4% | +28.5% | +3.1% | +13.8% | -1.2% |
| Aug 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.90 | $3.96 | +1.5% | -6.4% | +3.3% | -2.1% | +6.0% | -4.9% |
| Aug 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.26 | $4.32 | +1.4% | -5.9% | -2.7% | -6.4% | +3.3% | -2.1% |
| Jun 25 | Guggenheim | Maintains | Buy → Buy | — | $2.99 | $3.04 | +1.7% | +8.7% | -5.2% | -1.6% | -4.6% | -0.3% |
| Jun 24 | Wedbush | Maintains | Outperform → Outperform | — | $2.42 | $2.56 | +5.8% | +23.6% | +8.7% | -5.2% | -1.6% | -4.6% |
| Jun 24 | Guggenheim | Maintains | Buy → Buy | — | $2.42 | $2.56 | +5.8% | +23.6% | +8.7% | -5.2% | -1.6% | -4.6% |
| Mar 25 | Guggenheim | Maintains | Buy → Buy | — | $2.28 | $2.28 | +0.0% | +1.3% | -2.6% | +6.7% | -2.1% | -8.5% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.28 | $2.28 | +0.0% | +1.3% | -2.6% | +6.7% | -2.1% | -8.5% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $2.28 | $2.28 | +0.0% | +1.3% | -2.6% | +6.7% | -2.1% | -8.5% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.73 | +2.8% | -1.4% | -3.4% | +0.6% | +6.6% | +7.0% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.83 | $4.71 | -2.5% | -10.6% | -3.7% | -4.3% | +0.8% | -1.2% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.17 | $3.95 | -36.0% | -21.7% | -10.6% | -3.7% | -4.3% | +0.8% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.69 | $6.53 | -2.4% | -7.9% | +3.6% | -4.7% | +0.8% | +0.5% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.46 | $8.47 | +0.1% | -2.7% | -6.0% | -2.2% | -2.8% | +10.9% |
| May 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.10 | $7.39 | +4.1% | +12.7% | +14.2% | +4.0% | +4.0% | -3.9% |
| May 22 | Citigroup | Maintains | Buy → Buy | — | $7.89 | $7.89 | +0.0% | +0.1% | -5.4% | -5.2% | +4.2% | -4.2% |
| May 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.27 | $8.05 | +10.7% | +8.5% | +0.1% | -5.4% | -5.2% | +4.2% |
| Mar 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.70 | $8.41 | -3.3% | +0.0% | -4.0% | +2.9% | -0.7% | +0.4% |
| Mar 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.63 | $8.81 | +2.1% | +1.6% | +6.0% | -6.5% | +0.0% | -4.0% |
| Feb 13 | Citigroup | Maintains | Buy → Buy | — | $7.83 | $8.06 | +2.9% | +11.6% | +36.8% | +11.0% | -3.8% | -5.6% |
| Feb 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.83 | $8.06 | +2.9% | +11.6% | +36.8% | +11.0% | -3.8% | -5.6% |
| Nov 17 | Citigroup | Upgrade | Neutral → Buy | — | $3.09 | $3.25 | +5.2% | +6.5% | -4.6% | -1.9% | +7.8% | +5.4% |
| Aug 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.23 | $4.20 | -0.7% | -1.2% | -4.1% | -1.5% | -2.0% | +2.1% |
| Jun 20 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.30 | $3.30 | +0.0% | +5.5% | -0.3% | -3.2% | -1.5% | -1.8% |
| Jun 8 | Citigroup | Maintains | Neutral → Neutral | — | $3.70 | $3.71 | +0.3% | -5.1% | +4.0% | +3.6% | -1.6% | -0.8% |
| May 18 | Citigroup | Maintains | Neutral → Neutral | — | $3.69 | $3.61 | -2.2% | +2.2% | -2.9% | -0.8% | -0.3% | +1.1% |
| May 17 | Guggenheim | Maintains | Buy → Buy | — | $3.65 | $3.74 | +2.5% | +1.1% | +2.2% | -2.9% | -0.8% | -0.3% |
| May 16 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.59 | $3.60 | +0.3% | +1.7% | +1.1% | +2.2% | -2.9% | -0.8% |
| May 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.59 | $3.60 | +0.3% | +1.7% | +1.1% | +2.2% | -2.9% | -0.8% |
| May 15 | Citigroup | Maintains | Neutral → Neutral | — | $5.06 | $4.03 | -20.4% | -29.1% | +1.7% | +1.1% | +2.2% | -2.9% |
| Mar 15 | Guggenheim | Maintains | Buy → Buy | — | $5.90 | $5.87 | -0.5% | -1.9% | +1.0% | -8.0% | -10.2% | -1.7% |
| Mar 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.73 | $5.98 | +4.4% | +3.0% | -1.9% | +1.0% | -8.0% | -10.2% |
| Mar 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.06 | $6.44 | +6.3% | -4.0% | +8.2% | -0.6% | -5.0% | -0.3% |
| Jan 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.24 | $4.24 | +0.0% | +0.0% | +0.5% | -1.4% | +11.2% | +3.4% |
| Dec 13 | Citigroup | Maintains | Neutral → Neutral | — | $3.89 | $3.93 | +1.0% | +2.1% | +12.8% | +1.8% | -1.8% | +12.7% |
| Oct 19 | Guggenheim | Maintains | Buy → Buy | — | $3.45 | $3.59 | +4.1% | -0.6% | -2.9% | +0.6% | -12.5% | +2.0% |
| Sep 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.20 | $3.46 | +8.1% | +0.6% | -0.3% | +7.5% | -5.5% | +6.1% |
| Sep 19 | William Blair | Upgrade | Market Perform → Outperform | — | $3.20 | $3.46 | +8.1% | +0.6% | -0.3% | +7.5% | -5.5% | +6.1% |
| Feb 15 | William Blair | Downgrade | Outperform → Market Perform | — | $8.37 | $3.05 | -63.6% | -52.1% | -1.7% | -1.0% | -4.6% | -1.9% |
| Feb 1 | William Blair | Maintains | Outperform → Outperform | — | $15.71 | $16.31 | +3.8% | +8.2% | +11.6% | +3.6% | -3.8% | -2.0% |
No insider trades available.
8-K · 2.02
!! High
Larimar Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
Unknown — 8-K Filing
Larimar reported 2025 results as a clinical-stage biotech with no approved products, making cash burn and upcoming financing needs critical metrics that will likely determine stock viability through key development milestones.
Mar 19
8-K · 8.01
!! High
Larimar Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Larimar Therapeutics updated its investor presentation, signaling ongoing engagement with capital markets stakeholders regarding company strategy and operational developments.
Mar 9
8-K
Larimar Therapeutics, Inc. -- 8-K Filing
Larimar Therapeutics completed a securities offering with Citizens JMP Securities as lead manager and JonesTrading as co-manager, indicating the company raised capital through institutional channels.
Feb 27
8-K · 8.01
!! High
Larimar Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Larimar Therapeutics received FDA Breakthrough Therapy Designation for nomlabofusp treating Friedreich's ataxia, accelerating development and review timelines for this rare genetic neurological disorder therapy.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.p. | 35,606,974 | $160M | Added | Mar 2026 |
| 2 | Blue Owl Capital Holdings Lp | 7,120,007 | $32M | Added | Mar 2026 |
| 3 | Millennium Management | 3,625,278 | $16M | Reduced | Mar 2026 |
| 4 | Aigh Capital Management Llc | 3,000,000 | $14M | Added | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 2,866,349 | $13M | New | Mar 2026 |
| 6 | Rtw Investments, Lp | 1,500,000 | $7M | Reduced | Mar 2026 |
| 7 | Woodline Partners Lp | 1,400,850 | $6M | Added | Mar 2026 |
| 8 | Soleus Capital Management, L.p. | 1,066,960 | $5M | New | Mar 2026 |
| 9 | Point72 Asset Management | 1,047,385 | $5M | Reduced | Mar 2026 |
| 10 | Marshall Wace, Llp | 933,464 | $4M | New | Mar 2026 |
| 11 | Gem Investment Advisors, Llc | 854,230 | $4M | Added | Mar 2026 |
| 12 | Qube Research & Technologies Ltd | 847,644 | $4M | New | Mar 2026 |
| 13 | Aqr Capital Management Llc | 817,517 | $4M | Added | Mar 2026 |
| 14 | Renaissance Technologies Llc | 739,942 | $3M | Added | Mar 2026 |
| 15 | Nuveen, Llc | 674,915 | $3M | Added | Mar 2026 |
| 16 | Alyeska Investment Group, L.p. | 617,211 | $3M | Reduced | Mar 2026 |
| 17 | D.e. Shaw & Co | 575,624 | $3M | Added | Mar 2026 |
| 18 | Jane Street Group, Llc | 678,942 | $3M | Added | Dec 2025 |
| 19 | Citadel Advisors Llc | 519,132 | $2M | Reduced | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 475,612 | $2M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$268.4M
Enterprise Value
$131.6M
P/E (TTM)
-1.75x
Forward P/E
—
PEG Ratio
-0.02x
P/B
3.44x
P/S
—
P/FCF
-2.37x
EV/EBITDA
—
Shares Out
72.9M
Financials (TTM)
Revenue
$0
Net Income
-$166.0M
EBITDA
-$165.7M
Free Cash Flow
-$113.3M
Op Cash Flow
-$113.2M
EPS Basic
$-2.27
EPS Diluted
$-2.10
EPS Forward
$-1.93
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$145.8M
Total Liab.
$67.8M
Total Equity
$78.1M
Cash
$136.9M
LT Debt
$0
Book Value/Sh
$1.07
Debt/Equity
0.05x
Current Ratio
2.19
Quick Ratio
2.19
Returns & Growth
ROE
-212.2%
ROA
-113.6%
ROIC
-210.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-72.0%
Price Returns
2W
-10.5%
1M
-14.3%
3M
-34.5%
6M
-1.7%
12M
+54.7%
Technicals
52W High
$5.95
52W Low
$2.42
50d MA
$3.89
200d MA
$3.98
RSI (14)
61.00
ATR (14)
$0.24
Beta
1.02
Avg Volume
1.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 25, 2026 7:52pm
· Source: financialmodelingprep.com